• Enlivex Therapeutics is trading at $2.04 (5.99% down) in after-hours sessions, retracing a portion of its sharp rebound from last week’s dilution-driven selloff.
  • The decline likely reflects profit-taking and thin after-hours liquidity, occurring on the same day H.C. Wainwright significantly raised its price target on ENLV to $80.00 from $20.00.
  • This follows a recent $400 million private placement and a 1-for-15 reverse stock split in July, which contributed to recent volatility.